NeuraNova, rebranded from StrokeDx, competes in the same point-of-care stroke diagnostic race as Wellumio and Hyperfine but takes a bioimpedance and eddy-current sensing approach rather than a scaled-down MRI, aiming for a lower-cost bedside device (STEDI Scan) rather than diagnostic-grade imaging. Backing from MedTech Innovator, the Caltech endowment, and an NINDS grant signals early institutional validation, though the device remains pre-clearance.